Ralliant’s (RAL) Buy Rating Reiterated at Truist Financial

Truist Financial restated their buy rating on shares of Ralliant (NYSE:RAL) in a research report report published on Wednesday morning,Benzinga reports. Truist Financial currently has a $68.00 price objective on the stock, up from their prior price objective of $53.00.

Other analysts also recently issued research reports about the stock. Citigroup raised their price target on shares of Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday. Barclays raised their price target on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday. Zacks Research upgraded shares of Ralliant from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Vertical Research upgraded shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Friday, February 6th. Finally, Oppenheimer raised their price target on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $61.90.

Ralliant Stock Down 1.1%

Shares of NYSE RAL opened at $59.43 on Wednesday. The company has a 50 day simple moving average of $45.42 and a 200-day simple moving average of $47.52. The company has a market capitalization of $6.65 billion and a P/E ratio of -5.43. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 0.58. Ralliant has a 1 year low of $37.27 and a 1 year high of $62.35.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The business’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities research analysts predict that Ralliant will post 2.63 earnings per share for the current year.

Ralliant Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Insiders Place Their Bets

In related news, SVP Karen M. Bick sold 2,530 shares of Ralliant stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $46.50, for a total value of $117,645.00. Following the completion of the sale, the senior vice president owned 42,652 shares in the company, valued at approximately $1,983,318. This trade represents a 5.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional Trading of Ralliant

Institutional investors have recently added to or reduced their stakes in the stock. Danske Bank A S acquired a new stake in Ralliant in the 4th quarter valued at approximately $25,000. Allworth Financial LP grew its stake in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after acquiring an additional 293 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Ralliant in the fourth quarter worth $26,000. Westfuller Advisors LLC acquired a new position in shares of Ralliant in the third quarter worth $26,000. Finally, Palisade Asset Management LLC acquired a new position in shares of Ralliant in the third quarter worth $26,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.